UNITED THERAPEUTICS ($UTHR) posted quarterly earnings results for Q1 2026 on Wednesday, May 6th. The company reported earnings of $5.82 per share, missing estimates of $7.01 by $1.19. The company also reported revenue of $781,500,000, missing estimates of $812,859,328 by $-31,359,328.
You can see Quiver Quantitative's $UTHR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
UNITED THERAPEUTICS Insider Trading Activity
UNITED THERAPEUTICS insiders have traded $UTHR stock on the open market 1000 times in the past 6 months. Of those trades, 0 have been purchases and 1000 have been sales.
Here’s a breakdown of recent trading of $UTHR stock by insiders over the last 6 months:
- MARTINE A ROTHBLATT (Chairperson & CEO) has made 0 purchases and 546 sales selling 515,575 shares for an estimated $272,701,607.
- MICHAEL BENKOWITZ (PRESIDENT AND COO) has made 0 purchases and 123 sales selling 306,940 shares for an estimated $147,356,957.
- JAMES EDGEMOND (CFO AND TREASURER) has made 0 purchases and 223 sales selling 238,517 shares for an estimated $124,939,770.
- PAUL A MAHON (EVP & GENERAL COUNSEL) has made 0 purchases and 83 sales selling 102,100 shares for an estimated $51,211,176.
- LOUIS W SULLIVAN has made 0 purchases and 2 sales selling 5,950 shares for an estimated $3,047,200.
- CHRISTOPHER PATUSKY has made 0 purchases and 3 sales selling 4,910 shares for an estimated $2,730,623.
- TOMMY G THOMPSON has made 0 purchases and 5 sales selling 4,910 shares for an estimated $2,512,704.
- RAY KURZWEIL sold 4,910 shares for an estimated $2,401,088
- CHRISTOPHER CAUSEY has made 0 purchases and 4 sales selling 3,320 shares for an estimated $1,815,849.
- JUDY D. OLIAN has made 0 purchases and 4 sales selling 800 shares for an estimated $416,998.
- JAN MALCOLM has made 0 purchases and 5 sales selling 245 shares for an estimated $120,545.
- NILDA MESA sold 187 shares for an estimated $90,064
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
UNITED THERAPEUTICS Hedge Fund Activity
We have seen 412 institutional investors add shares of UNITED THERAPEUTICS stock to their portfolio, and 362 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 1,042,711 shares (+74.5%) to their portfolio in Q4 2025, for an estimated $508,060,934
- DARWIN GLOBAL MANAGEMENT, LTD. removed 748,550 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $364,730,987
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 609,421 shares (-75.0%) from their portfolio in Q4 2025, for an estimated $296,940,382
- AVORO CAPITAL ADVISORS LLC added 583,838 shares (+28.9%) to their portfolio in Q4 2025, for an estimated $284,475,065
- CITIGROUP INC removed 367,062 shares (-66.6%) from their portfolio in Q4 2025, for an estimated $178,850,959
- JANUS HENDERSON GROUP PLC added 341,383 shares (+75.1%) to their portfolio in Q4 2025, for an estimated $166,338,866
- BAILLIE GIFFORD & CO added 323,016 shares (+inf%) to their portfolio in Q4 2025, for an estimated $157,389,546
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
UNITED THERAPEUTICS Government Contracts
We have seen $1,495,547 of award payments to $UTHR over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TYVASO KITS & CARTRIDGES: $379,307
- OPSUMIT 10MG-QTY 4 @ $6,270.03 ADEMPAS 1MG, QTY 1 @ $12,153.05 REMODULIN 5MG/ML INJ 20ML VIAL, QTY 1 @ $6,2...: $49,773
- OPSUMIT 10MG-QTY 2 @ 6,270.03 ADEMPAS 1MG, QTY 1 @ 12,153.05 JULY 2025: $37,233
- OPSUMIT 10MG-QTY 4 @ 6,270.03 ADEMPAS 1MG, QTY 1 @ 12,153.05 SEPT FY25: $37,233
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
UNITED THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $UTHR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/06/2026
To track analyst ratings and price targets for UNITED THERAPEUTICS, check out Quiver Quantitative's $UTHR forecast page.
UNITED THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $UTHR recently. We have seen 9 analysts offer price targets for $UTHR in the last 6 months, with a median target of $626.0.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $519.0 on 04/10/2026
- Benjamin Burnett from Wells Fargo set a target price of $575.0 on 03/31/2026
- Greg Harrison from B of A Securities set a target price of $626.0 on 03/31/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $660.0 on 03/31/2026
- Joseph Thome from TD Cowen set a target price of $660.0 on 03/30/2026
- Olivia Brayer Saunders from Cantor Fitzgerald set a target price of $625.0 on 03/12/2026
- Ashwani Verma from UBS set a target price of $705.0 on 03/05/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
